Received: 16 March 2022
Accepted: 23 June 2022
First Online: 11 July 2022
: This study was approved by the Ethics Committee of the Hospital District of Southwest Finland (decision 58/1803/2018), and was conducted according to the principles of the Declaration of Helsinki. Informed consent in this retrospective study was waived by the Ethics Committee of the Hospital District of Southwest Finland.
: Not applicable.
: LS has received funding from the state research funding of the Turku University Hospital, district of Southwest Finland, funding from The Finnish Parkinson Foundation and a travel grant from the Doctoral Programme in Clinical Research of the University of Turku. EB has received research grant from the Clinical Research Track of the University of Turku. PW has nothing to report. MG has received research funding from medical support association Liv och Hälsa, finnish Medical Association, K Albin Johansson foundation, Perklén foundation. VK has received grants from the Finnish Foundation for Alcohol Studies, the Päivikki and Sakari Sohlberg Foundation, the Finnish Cultural Foundation, the Turku University Foundation and the Michael J. Fox Foundation, consulting fees from Nordic Infucare AB, has served in advisory boards for Abbvie and Nordic Infucare AB and has received speaker honoraria from Abbvie, GE Healthcare, Nordic Infucare, Teva and Orion Pharma.